New Report on AZT

Helquist, Michael
January 1989
Advocate;1/17/89, Issue 516, p30
Reports on a study indicating that azidothymidine (AZT) can reverse the deterioration in mental and cognitive capabilities often experienced by individuals with AIDS or AIDS-related complex. Support for anecdotal reports on the benefits of the antiviral drug; Details of the study.


Related Articles

  • AZT: Prolonging Life But Not Stopping Death. Helquist, Michael // Advocate;3/3/87, Issue 467, p23 

    Reports that the medical advisers of the U.S. Food and Drug Administration have recommended in 1987 the licensing of AZT for sale to a restricted group of patients with AIDS or severe ARC. Initial results of studies on AZT; Benefits from taking AZT; Researchers' concerns about side effects.

  • OKLAHOMA.  // Advocate;11/3/92, Issue 615, p26 

    Reports that Oklahoma state-subsidized distribution of the antiviral drug, AZT to indigent people will be stopped because of a bureaucratic problem that caused officials at state agencies to fail to report that the program was in jeopardy.

  • AZT combination trial shows positive results.  // Nature;9/28/1995, Vol. 377 Issue 6547, p276 

    Reports on the result of a study on the effects of AZT when given jointly with one of two antiretoviral drugs in patients with HIV or AIDS in London, England.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Nov2002, Vol. 16 Issue 11, p567 

    Presents news and developments relevant to antiviral drugs compiled as of November 2002. Treatment interruption of antiretroviral therapy; Cases of bradyarrhythmia; Resistance of HIV strains to AZT.

  • YET MORE BUSHWHACKING.  // Advocate;10/9/90, Issue 561, p10 

    Reports on the growing concern over the lack of access to the drug, AZT for HIV-infected people and AIDS patients. Examples of the most common excuses the hinder access to the drug.

  • Another Look at AZT Report. Helquist, Michael // Advocate;1/5/88, Issue 489, p23 

    Reports that AZT may not block indefinitely the progression of AIDS according to study findings from the University of Miami School of Medicine. Details of the study.

  • NEWSFRONT: NORTH CAROLINA.  // Advocate;1/5/88, Issue 489, p31 

    Reports that officials of North Carolina-based Burroughs Wellcome Co. agreed to meet with New York State lawmaker, Gerrold Nadler about their pricing policy for the anti-AIDS drug, AZT.

  • Differential scanning microcalorimetry study of thermal stability of nevirapine and azidothymidine mixture. Michalik, K.; Drzazga, Zofia; Michnik, Anna; Kaszuba, M. // Journal of Thermal Analysis & Calorimetry;Apr2006, Vol. 84 Issue 1, p119 

    A differential scanning calorimetry study of the thermal behavior of nevirapine and azidothymidine in water solution was carried out. For nevirapine scan rate dependent and irreversible endothermic peak were found. Thermal degradation of nevirapine as well as NVP – AZT mixture is...

  • In--Vitro Resistance to Zidovudine and Alpha--Interferon in HIV--1 Isolates from Patients: Correlations with Treatment Duration and Response. Edlin, Brian R.; St. Clair, Marty H.; Pitha, P.M.; Whaling, Susan M. // Annals of Internal Medicine;9/15/92, Vol. 117 Issue 6, p457 

    Presents a study that measured in-vitro antiviral drug susceptibilities of human immunodeficiency virus type 1 isolates recovered from patients treated with alpha-interferon or zidovudine and patients not treated with these drugs. Methodology; Results and discussion; Conclusion.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics